Allometric scaling of pegylated liposomal anticancer drugs

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 38, Issue 5, 2011, Pages 653-669

  Caron, Whitney P ^a   Clewell, Harvey ^b   Dedrick, Robert ^c   Ramanathan, Ramesh K ^d   Davis, Whitney L ^a   Yu, Ning ^e   Tonda, Margaret ^e   Schellens, Jan H ^f   Beijnen, Jos H ^f   Zamboni, William C ^a,g  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b Hamner Institute for Health Sciences   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e ALZA CORPORATION   (United States)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Allometric; Anticancer drugs; Dedrick Plot; Mononuclear phagocyte system (MPS); Pegylated liposomes; Preclinical

Indexed keywords

ANTINEOPLASTIC AGENT; CDK 602; CISPLATIN; CKD 605; DOXORUBICIN; LIPOSOME; UNCLASSIFIED DRUG;

ALLOMETRY; ARTICLE; BODY WEIGHT; CORRELATION ANALYSIS; DEDRICK PLOTS; DOG; DRUG CLEARANCE; DRUG DISPOSITION; DRUG FORMULATION; DRUG TOLERABILITY; FEASIBILITY STUDY; HUMAN; KIDNEY MASS; LEUKOCYTE COUNT; LIVER BLOOD FLOW; LIVER WEIGHT; MATHEMATICAL PARAMETERS; MAXIMUM LIFE SPAN POTENTIAL; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPECIES DIFFERENCE; SPLEEN BLOOD FLOW; SPLEEN WEIGHT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CAMPTOTHECIN; CISPLATIN; CLINICAL TRIALS, PHASE I AS TOPIC; DOGS; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; MALE; MICE; MODELS, THEORETICAL; NEOPLASMS; POLYETHYLENE GLYCOLS; RATS; SOFTWARE; SPECIES SPECIFICITY; TIME FACTORS;

EID: 84860393338     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-011-9213-5     Document Type: Article

References (46)

1. RK Jain 1996 Delivery of molecular medicine to solid tumors Science 271 5252 1079 1080 8599082 10.1126/science.271.5252.1079 1:CAS:528: DyaK28Xht1GksLg%3D (Pubitemid 26075221)
2. WC Zamboni PJ Houghton JL Hulstein M Kirstein J Walsh PK Cheshire SK Hanna MK Danks CF Stewart 1999 Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines Cancer Chemother Pharmacol 43 4 269 276 10071976 10.1007/ s002800050894 1:CAS:528:DyaK1MXhvFWrsrk%3D (Pubitemid 29075882)
3. B Blochl-Daum M Muller V Meisinger HG Eichler A Fassolt H Phemaberger 1996 Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis Br J Cancer 73 7 920 924 8611407 10.1038/bjc.1996.164 1:CAS:528:DyaK28XislKqs7Y%3D (Pubitemid 26110164)
4. M Muller RM Mader B Steiner GG Steger B Jansen M Gnant T Helbich R Jakesz HG Eichler B Blochl-Daum 1997 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients Cancer Res 57 13 2598 2601 9205062 1:CAS:528:DyaK2sXkt12ru7k%3D (Pubitemid 27283765)
5. DC Drummond O Meyer K Hong DB Kirpotin D Papahadjopoulos 1999 Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol Rev 51 4 691 743 10581328 1:CAS:528:DC%2BD3cXnslChsLg%3D
6. WC Zamboni 2005 Liposomal, nanoparticle, and conjugated formulations of anticancer agents Clin Cancer Res 11 23 8230 8234 16322279 10.1158/1078-0432. CCR-05-1895 1:CAS:528:DC%2BD2MXht1KjsrvL (Pubitemid 41746931)
7. D Papahadjopoulos TM Allen A Gabizon E Mayhew K Matthay SK Huang KD Lee MC Woodle DD Lasic C Redemann 1991 Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc Natl Acad Sci USA 88 24 11460 11464 1763060 10.1073/pnas.88.24.11460 1:CAS:528: DyaK38XmslWjsg%3D%3D (Pubitemid 21916061)
8. A D'Emanuele D Attwood 2005 Dendrimer-drug interactions Adv Drug Deliv Rev 57 15 2147 2162 16310283 10.1016/j.addr.2005.09.012 (Pubitemid 41760432)
9. TM Allen FJ Martin 2004 Advantages of liposomal delivery systems for anthracyclines Semin Oncol 31 6 Suppl 13 5 15 15717735 10.1053/j.seminoncol. 2004.08.001 1:CAS:528:DC%2BD2MXhtVyns7g%3D (Pubitemid 40023239)
10. Allen TM, Stuart DD. Liposome pharmacokinetics: Classical, sterically-stabilized, cationic liposomes and immunoliposomes. In: Janoff AS (ed) Liposomes: rational design. Marcel Dekker, Inc., New York, pp 63-87
11. H Maeda J Wu T Sawa Y Matsumura K Hori 2000 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J Control Release 65 1-2 271 284 10699287 10.1016/S0168-3659(99)00248-5 1:CAS:528: DC%2BD3cXhtl2qsLo%3D (Pubitemid 30122932)
12. JH Lee JM Lee KH Lim JK Kim SK Ahn YJ Bang CI Hong 2000 Preclinical and phase I clinical studies with CKD-602, a novel camptothecin derivative Ann NY Acad Sci 922 324 325 11193913 10.1111/j.1749-6632.2000.tb07055.x 1:CAS:528:DC%2BD3MXntVGjsg%3D%3D (Pubitemid 32050270)
13. WC Zamboni S Strychor E Joseph DR Walsh BA Zamboni RA Parise ME Tonda NY Yu C Engbers JL Eiseman 2007 Plasma, tumor and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts Clin Cancer Res 13 23 7217 7223 18056203 10.1158/1078-0432.CCR-07-1035 1:CAS:528:DC%2BD2sXhtlyitLjM (Pubitemid 350276909)
14. A Gabizon H Shmeeda Y Barenholz 2003 Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies Clin Pharmacokinet 42 5 419 436 12739982 10.2165/00003088-200342050-00002 1:CAS:528: DC%2BD3sXkvFOjsrY%3D (Pubitemid 36649037)
15. A Gabizon R Isacson O Rosengarten D Tzemach H Shmeeda R Sapir 2008 An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin Cancer Chemother Pharmacol 61 4 695 702 17549475 10.1007/s00280-007-0525-5 1:CAS:528:DC%2BD1cXjsFWqsg%3D%3D
16. JM Meerum Terwogt G Groenewegen D Pluim M Maliepaard MM Tibben A Huisman WW ten Bokkel Huinink M Schot H Welbank EE Voest JH Beijnen JM Schellens 2002 Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin Cancer Chemother Pharmacol 49 3 201 210 11935212 10.1007/s002800100371 1:CAS:528:DC%2BD38XhtlSrsr0%3D (Pubitemid 34185593)
17. JM Meerum Terwogt MM Tibbem H Wellbank JH Schellens JH Beijnen 2000 Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry Fresenius J Anal Chem 366 3 298 302 11225675 10.1007/s002160050056 1:CAS:528:DC%2BD3cXntl2rsw%3D%3D
18. I Mahmood JD Balian 1999 The pharmacokinetic principles behind scaling from preclinical results to phase I protocols Clin Pharmacokinet 36 1 1 11 9989339 10.2165/00003088-199936010-00001 1:STN:280:DyaK1M7ktl2gsw%3D%3D (Pubitemid 29055997)
19. JH Lin 1995 Species similarities and differences in pharmacokinetics Drug Metab Dispos 23 10 1008 1021 8654187 1:CAS:528:DyaK2MXovFGksbw%3D
20. L Lindstedt PJ Schaeffer 2002 Use of allometry in predicting anatomical and physiological parameters of mammals Lab Anim 36 1 1 19 11833526 10.1258/0023677021911731 1:CAS:528:DC%2BD38XitFyqsb4%3D (Pubitemid 34073118)
21. I Mahmood JD Balian 1996 Interspecies scaling: predicting clearance of drugs in humans Xenobiotica 26 9 887 895 8893036 10.3109/00498259609052491 1:CAS:528:DyaK28XmtVyntrs%3D (Pubitemid 26343083)
22. McNamara PG (1991) Interspecies scaling in pharmacokinetics. In: Welling PG, Tse FLS, Dighe SV (eds) Pharmaceutical bioequivalence. Marcel Dekker Inc, New York, pp 276-300
23. H Boxenbaum 1984 Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm Drug Metab Rev 15 5-6 1071 1121 6396053 10.3109/03602538409033558 1:CAS:528:DyaL2MXnt1WksQ%3D%3D (Pubitemid 15158037)
24. Sacher G (1959) Relation of lifespan to brain weight and body weight in mammals. In: Wolstenholme GEW, O'Connor M (eds) CIBA Foundation colloquia on aging. Churchill, London, pp 115-133
25. H Boxenbaum R Ronfeld 1983 Interspecies pharmacokinetic scaling and the Dedrick plots Am J Physiol 245 6 768 777
26. R Dedrick KB Bischoff DS Zaharko 1970 Interspecies correlation of plasma concentration history of methotrexate (NSC-740) Cancer Chemother Rep 54 2 95 101 5003581 1:CAS:528:DyaE3cXksVersLc%3D
27. H Boxenbaum 1982 Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics J Pharmacokinet Biopharm 10 2 201 227 7120049 10.1007/BF01062336 1:CAS:528:DyaL38Xlt1Sjtbo%3D (Pubitemid 12044187)
28. RP Brown MD Delp SL Lindstedt LR Rhomberg RP Beliles 1997 Physiological parameter values for physiologically based pharmacokinetic models Toxicol Ind Health 13 4 407 484 9249929 1:CAS:528:DyaK2sXltl2itrk%3D (Pubitemid 27314117)
29. Food and Drug Administration 2003 Draft guidance for industry and reviewers on estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers Fed Regist 68 2340 2341
30. K Schneider J Oltmanns M Hassauer 2004 Allometric principles for interspecies extrapolation in toxicological risk assessment-empirical investigations Regul Toxicol Pharmacol 39 3 334 347 15135212 10.1016/j.yrtph.2004.03.001 1:CAS:528:DC%2BD2cXjvVemsLo%3D (Pubitemid 38596769)
31. JN Sweeting M Siu GP McCallum L Miller PG Wells 2010 Species differences in methanol and formic acid pharmacokinetics in mice, rabbits and primates Toxicol Appl Pharmacol 247 1 28 35 20510256 10.1016/j.taap.2010.05.009 1:CAS:528:DC%2BC3cXptVCntLs%3D
32. PL Toutain A Ferran A Bousquet-Melou 2010 Species differences in pharmacokinetics and pharmacodynamics Handb Exp Pharmacol 199 19 48 20204582 10.1007/978-3-642-10324-7-2 1:CAS:528:DC%2BC3cXosl2jtbc%3D
33. RP Hunter 2010 Interspecies allometric scaling Handb Exp Pharmacol 199 139 157 20204586 10.1007/978-3-642-10324-7-6 1:CAS:528:DC%2BC3cXosl2jurk%3D
34. RL Dedrick 1973 Animal scale-up J Pharmacokinet Biopharm 1 5 435 461 4787619 10.1007/BF01059667 1:CAS:528:DyaE2cXktVSjsLg%3D
35. Calder WA (1984) Size, function and life history. Harvard University Press, Cambridge, Massachusetts
36. O Yamato M Hayashi E Kasai M Tajima M Yamasaki Y Maede 1999 Reduced glutathione accelerates the oxidative damage produced by sodium n-propylthiosulfate, one of the causative agents of onion-induced hemolytic anemia in dogs Biochem Biophys Acta 1427 2 175 182 10216234 1:CAS:528: DyaK1MXis1aksr4%3D (Pubitemid 29182769)
37. H Tang M Mayersohn 2011 Controversies in allometric scaling for predicting human drug clearance: an historical problem and reflections on what works and what does not Curr Top Med Chem 11 4 340 350 21320063 10.2174/156802611794480945 1:CAS:528:DC%2BC3MXkslSntbY%3D
38. KA Quigley BJ Chelack DM Haines ML Jackson 2001 Application of a direct flow cytometric erythrocyte immunofluorescence assay in dogs with immune-mediated hemolytic anemia and comparison to the direct antiglobulin test J Vet Diagn Invest 13 4 297 300 11478600 10.1177/104063870101300403 1:STN:280:DC%2BD38%2Fis1CqtA%3D%3D (Pubitemid 33646012)
39. WC Zamboni LJ Maruca S Strychor BA Zamboni S Ramalingam RP Edwards J Kim Y Bang H Lee DM Friedland RG Stoller CP Belani RK Ramanathan 2010 Bidirectional pharmacodynamics interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors J Liposome Res 21 2 158 165 20626314 10.3109/08982104.2010.496085
40. Duncan JR, Prusse KW, Mahaffey EA (1994) Veterinary laboratory medicine clinical pathology, 3rd edn. Iowa State Univ Press, Ames, Iowa, p 235
41. Treseler KM (1995) Clinical laboratory and diagnostic tests, 3rd edn. Appleton and Lange, Norwalk, Connecticut, p 117
42. Fischbach F (2004) A manual of laboratory diagnostic tests, 7th edn. Lippincottand Wilkins, Philadelphia, Pennsylvania, p 47
43. Sharp PE, LaRegina MC (1998) The laboratory rat. CRC Press, Boston, Massachussetts, pp 4-11
44. WC Zamboni S Strychor L Maruca S Ramalingam BA Zamboni H Wu DM Friedland RP Edwards RG Stroller CP Belani RK Ramanathan 2009 Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies Clin Pharmacol Ther 86 5 519 526 19675541 10.1038/clpt.2009.141 1:CAS:528:DC%2BD1MXht1ymsrjK
45. H Wu JR Infante SF Jones HA Burris E Chan VL Keedy JC Bendell BA Zamboni H Kodaira S Ikeda WC Zamboni 2009 Factors affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors Mol Cancer Ther 8 12 C124
46. M Li KT Al-Jamal K Kosarelos J Reineke 2010 Physiologically based pharmacokinetic modeling of nanoparticles ACS Nano 4 11 3617 6303